Small peptide-based GLP-1R ligands: an approach to reduce the kidney uptake of radiolabeled GLP-1R-targeting agents?
Abstract Aim Elevated kidney uptake in insulinoma patients remains a major limitation of radiometallated exendin-derived ligands of the glucagon-like peptide 1 receptor (GLP-1R). Based on the previously published potent GLP-1R-activating undecapeptide 1, short-chained GLP-1R ligands were developed t...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
SpringerOpen
2021-08-01
|
Series: | EJNMMI Radiopharmacy and Chemistry |
Subjects: | |
Online Access: | https://doi.org/10.1186/s41181-021-00136-x |
id |
doaj-85bb54f77a4e48a8ba6a70e1ead711b3 |
---|---|
record_format |
Article |
spelling |
doaj-85bb54f77a4e48a8ba6a70e1ead711b32021-08-29T11:28:17ZengSpringerOpenEJNMMI Radiopharmacy and Chemistry2365-421X2021-08-016111610.1186/s41181-021-00136-xSmall peptide-based GLP-1R ligands: an approach to reduce the kidney uptake of radiolabeled GLP-1R-targeting agents?Veronika Barbara Felber0Hans-Jürgen Wester1Chair of Pharmaceutical Radiochemistry, Technical University of MunichChair of Pharmaceutical Radiochemistry, Technical University of MunichAbstract Aim Elevated kidney uptake in insulinoma patients remains a major limitation of radiometallated exendin-derived ligands of the glucagon-like peptide 1 receptor (GLP-1R). Based on the previously published potent GLP-1R-activating undecapeptide 1, short-chained GLP-1R ligands were developed to investigate whether kidney uptake can be reduced by means of direct 18F-labeling (nuclide-based accelerated renal excretion) or the reduction of the overall ligand charge (ligand-based reduced kidney uptake). Materials & methods GLP-1R ligands were prepared according to optimized standard protocols via solid-phase peptide synthesis (SPPS) or, when not practicable, via fragment coupling in solution. Synthesis of (2‘-Et, 4‘-OMe)4, 4’-L-biphenylalanine ((2′-Et, 4′-OMe)BIP), required for the preparation of 1, was accomplished by Suzuki-Miyaura cross-coupling. In vitro experiments were performed using stably transfected GLP-1R+ HEK293-hGLP-1R cells. Results In contrast to the three reference ligands glucagon-like peptide 1 (GLP-1, IC50 = 23.2 ± 12.2 nM), [Nle14, Tyr(3-I)40]exendin-4 (IC50 = 7.63 ± 2.78 nM) and [Nle14, Tyr40]exendin-4 (IC50 = 9.87 ± 1.82 nM), the investigated GLP-1R-targeting small peptides (9–15 amino acids), including lead peptide 1, exhibited only medium to low affinities (IC50 > 189 nM). Only SiFA-tagged undecapeptide 5 (IC50 = 189 ± 35 nM) revealed a higher affinity than 1 (IC50 = 669 ± 242 nM). Conclusion The investigated small peptides, including lead peptide 1 , could not compete with favorable in vitro characteristics of glucagon-like peptide 1 (GLP-1), [Nle14, Tyr(3-I)40]exendin-4 and [Nle14, Tyr40]exendin-4. The auspicious EC50 values of 1 provided by the literature could not be transferred to competitive binding experiments. Therefore, the use of 1 as a basic scaffold for the design of further GLP-1R-targeting radioligands cannot be recommended. Further investigations might include the scaffold of 5, although substantial optimizations concerning affinity and lipophilicity would be required. In sum, GLP-1R-targeting radioligands with reduced kidney uptake could not be obtained in this work, which emphasizes the need for further ligands addressing this particular issue.https://doi.org/10.1186/s41181-021-00136-xGLP-1RSmall peptidesInsulinomaDiagnosisPeptide receptor radionuclide therapyKidneys |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Veronika Barbara Felber Hans-Jürgen Wester |
spellingShingle |
Veronika Barbara Felber Hans-Jürgen Wester Small peptide-based GLP-1R ligands: an approach to reduce the kidney uptake of radiolabeled GLP-1R-targeting agents? EJNMMI Radiopharmacy and Chemistry GLP-1R Small peptides Insulinoma Diagnosis Peptide receptor radionuclide therapy Kidneys |
author_facet |
Veronika Barbara Felber Hans-Jürgen Wester |
author_sort |
Veronika Barbara Felber |
title |
Small peptide-based GLP-1R ligands: an approach to reduce the kidney uptake of radiolabeled GLP-1R-targeting agents? |
title_short |
Small peptide-based GLP-1R ligands: an approach to reduce the kidney uptake of radiolabeled GLP-1R-targeting agents? |
title_full |
Small peptide-based GLP-1R ligands: an approach to reduce the kidney uptake of radiolabeled GLP-1R-targeting agents? |
title_fullStr |
Small peptide-based GLP-1R ligands: an approach to reduce the kidney uptake of radiolabeled GLP-1R-targeting agents? |
title_full_unstemmed |
Small peptide-based GLP-1R ligands: an approach to reduce the kidney uptake of radiolabeled GLP-1R-targeting agents? |
title_sort |
small peptide-based glp-1r ligands: an approach to reduce the kidney uptake of radiolabeled glp-1r-targeting agents? |
publisher |
SpringerOpen |
series |
EJNMMI Radiopharmacy and Chemistry |
issn |
2365-421X |
publishDate |
2021-08-01 |
description |
Abstract Aim Elevated kidney uptake in insulinoma patients remains a major limitation of radiometallated exendin-derived ligands of the glucagon-like peptide 1 receptor (GLP-1R). Based on the previously published potent GLP-1R-activating undecapeptide 1, short-chained GLP-1R ligands were developed to investigate whether kidney uptake can be reduced by means of direct 18F-labeling (nuclide-based accelerated renal excretion) or the reduction of the overall ligand charge (ligand-based reduced kidney uptake). Materials & methods GLP-1R ligands were prepared according to optimized standard protocols via solid-phase peptide synthesis (SPPS) or, when not practicable, via fragment coupling in solution. Synthesis of (2‘-Et, 4‘-OMe)4, 4’-L-biphenylalanine ((2′-Et, 4′-OMe)BIP), required for the preparation of 1, was accomplished by Suzuki-Miyaura cross-coupling. In vitro experiments were performed using stably transfected GLP-1R+ HEK293-hGLP-1R cells. Results In contrast to the three reference ligands glucagon-like peptide 1 (GLP-1, IC50 = 23.2 ± 12.2 nM), [Nle14, Tyr(3-I)40]exendin-4 (IC50 = 7.63 ± 2.78 nM) and [Nle14, Tyr40]exendin-4 (IC50 = 9.87 ± 1.82 nM), the investigated GLP-1R-targeting small peptides (9–15 amino acids), including lead peptide 1, exhibited only medium to low affinities (IC50 > 189 nM). Only SiFA-tagged undecapeptide 5 (IC50 = 189 ± 35 nM) revealed a higher affinity than 1 (IC50 = 669 ± 242 nM). Conclusion The investigated small peptides, including lead peptide 1 , could not compete with favorable in vitro characteristics of glucagon-like peptide 1 (GLP-1), [Nle14, Tyr(3-I)40]exendin-4 and [Nle14, Tyr40]exendin-4. The auspicious EC50 values of 1 provided by the literature could not be transferred to competitive binding experiments. Therefore, the use of 1 as a basic scaffold for the design of further GLP-1R-targeting radioligands cannot be recommended. Further investigations might include the scaffold of 5, although substantial optimizations concerning affinity and lipophilicity would be required. In sum, GLP-1R-targeting radioligands with reduced kidney uptake could not be obtained in this work, which emphasizes the need for further ligands addressing this particular issue. |
topic |
GLP-1R Small peptides Insulinoma Diagnosis Peptide receptor radionuclide therapy Kidneys |
url |
https://doi.org/10.1186/s41181-021-00136-x |
work_keys_str_mv |
AT veronikabarbarafelber smallpeptidebasedglp1rligandsanapproachtoreducethekidneyuptakeofradiolabeledglp1rtargetingagents AT hansjurgenwester smallpeptidebasedglp1rligandsanapproachtoreducethekidneyuptakeofradiolabeledglp1rtargetingagents |
_version_ |
1721186827879055360 |